Calamos Advisors LLC Makes New $622,000 Investment in Novartis AG $NVS

Calamos Advisors LLC bought a new position in shares of Novartis AG (NYSE:NVS) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 4,073 shares of the company’s stock, valued at approximately $622,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NVS. J.W. Cole Advisors Inc. lifted its stake in shares of Novartis by 0.6% in the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after purchasing an additional 64 shares during the period. Roundview Capital LLC grew its position in Novartis by 2.5% during the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after buying an additional 66 shares during the period. IMA Advisory Services Inc. grew its position in Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after buying an additional 70 shares during the period. Abundance Wealth Counselors increased its holdings in Novartis by 0.4% in the fourth quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock valued at $2,334,000 after buying an additional 73 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC increased its holdings in Novartis by 3.5% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock valued at $307,000 after buying an additional 75 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Sanford C. Bernstein raised Novartis to a “hold” rating in a research note on Thursday, March 19th. Finally, Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Price Performance

NVS stock opened at $152.69 on Friday. The stock’s 50 day moving average price is $151.26 and its 200 day moving average price is $151.59. The firm has a market cap of $291.36 billion, a P/E ratio of 21.88, a PEG ratio of 2.60 and a beta of 0.45. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The company had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business’s revenue was down .9% compared to the same quarter last year. During the same period last year, the firm earned $2.28 earnings per share. On average, sell-side analysts expect that Novartis AG will post 8.76 earnings per share for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.